Therefore, in this study, the synergistic effects of STING and TLR9 agonists and the immunological mechanisms underlying tumor regression and CAFs’ infiltration of the TME were studied in a preclinical colorectal tumor model. This evidence concerns the gene STING1 and neoplasm.